{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:00:11Z","timestamp":1772164811766,"version":"3.50.1"},"reference-count":37,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":239,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Yttrium-90 (90Y) transarterial radioembolization can safely and effectively treat hepatocellular carcinoma (HCC). Clinical trials combining 90Y with immunotherapy are aimed at improving treatment response rates. The impact of transient 90Y-induced lymphopenia on T-cell homeostasis and functional dynamics is unknown. Paired blood specimens were collected prior to first-cycle 90Y and at imaging follow-up in patients with HCC Barcelona Clinic Liver Cancer stages A\u2013B. Flow cytometry and T-cell receptor (TCR) sequencing were used to monitor changes in T-cell subsets and TCR repertoire following 90Y. Objective response (OR) rates were determined using modified RECIST and defined as either OR or nonobjective response. Time-to-progression (TTP) was defined as progression to Barcelona Clinic Liver Cancer stage C within 6 months following 90Y. 90Y induced shifts in both CD4+ (P = 0.049) and CD8+ (P &amp;lt; 0.001) toward an effector memory T-cell response independent of treatment response rate. Nonresponders to 90Y were characterized by a sustained elevation in both na\u00efve CD4+ cells (P = 0.019) and programmed cell death protein 1 expression in CD8+ cells (P = 0.003). Paired analysis of the TCR repertoire revealed a variable induction of neoantigen clonotypes and expansion of existing clonotypes independent of 90Y response. In patients with an OR, changes in TCR clonality did not influence TTP. However, polyclonal profiles in patients without an OR were associated with shorter TTP (P = 0.005; HR, 10.8) and 75% disease progression rates 6 months following treatment. 90Y induces a population shift from central to effector memory accompanied by neoantigen T-cell responses independent of treatment response rate. Monoclonal shifts in the post-90Y T-cell repertoire had superior overall TTP and improved TTP in patients with a first-cycle nonobjective response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>90Y can safely treat HCC; however, it causes transient lymphopenia. In this article, 90Y stimulates a peripheral effector memory response independent of initial treatment response. TCR sequencing revealed that polyclonal profiles in patients without an OR to treatment were associated with rapid progression rates 6 months after 90Y.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0228","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:43:11Z","timestamp":1722213791000},"page":"2163-2173","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-317X","authenticated-orcid":false,"given":"Kelley","family":"N\u00fa\u00f1ez","sequence":"first","affiliation":[{"name":"Institute of Translational Research, Ochsner Health System, New Orleans, Louisiana. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-7357","authenticated-orcid":false,"given":"Tyler","family":"Sandow","sequence":"additional","affiliation":[{"name":"Interventional Radiology, Ochsner Health System, New Orleans, Louisiana. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3975-9343","authenticated-orcid":false,"given":"Juan","family":"Gimenez","sequence":"additional","affiliation":[{"name":"Interventional Radiology, Ochsner Health System, New Orleans, Louisiana. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0515-3764","authenticated-orcid":false,"given":"Mina","family":"Hibino","sequence":"additional","affiliation":[{"name":"Institute of Translational Research, Ochsner Health System, New Orleans, Louisiana. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-8647","authenticated-orcid":false,"given":"Ari","family":"Cohen","sequence":"additional","affiliation":[{"name":"Multi-Organ Transplant Institute, Ochsner Health System, New Orleans, Louisiana. 3"},{"name":"Faculty of Medicine, University of Queensland, Brisbane, Australia. 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6483-6259","authenticated-orcid":false,"given":"Paul","family":"Thevenot","sequence":"additional","affiliation":[{"name":"Institute of Translational Research, Ochsner Health System, New Orleans, Louisiana. 1"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"2025032809291913500_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"2025032809291913500_bib2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025032809291913500_bib3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025032809291913500_bib4","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"2025032809291913500_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025032809291913500_bib6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2025032809291913500_bib7","doi-asserted-by":"crossref","first-page":"592","DOI":"10.21037\/hbsn-22-143","article-title":"Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2025032809291913500_bib8","doi-asserted-by":"crossref","first-page":"113442","DOI":"10.1016\/j.ejca.2023.113442","article-title":"Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization - implications in treatment outcomes","volume":"196","author":"N\u00fa\u00f1ez","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025032809291913500_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","journal-title":"Gut"},{"key":"2025032809291913500_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/gutjnl-2021-326869","article-title":"Y90-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers","volume":"72","author":"Rivoltini","year":"2023","journal-title":"Gut"},{"key":"2025032809291913500_bib11","doi-asserted-by":"crossref","first-page":"587014","DOI":"10.3389\/fimmu.2020.587014","article-title":"Characteristics of TCR repertoire associated with successful immune checkpoint therapy responses","volume":"11","author":"Kidman","year":"2020","journal-title":"Front Immunol"},{"key":"2025032809291913500_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"2025032809291913500_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/path.4260","article-title":"High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer","volume":"231","author":"Emerson","year":"2013","journal-title":"J Pathol"},{"key":"2025032809291913500_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"2025032809291913500_bib15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fonc.2014.00198","article-title":"Side effects of yttrium-90 radioembolization","volume":"4","author":"Riaz","year":"2014","journal-title":"Front Oncol"},{"key":"2025032809291913500_bib16","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2018.01613","article-title":"Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer","volume":"9","author":"Manjarrez-Ordu\u00f1o","year":"2018","journal-title":"Front Immunol"},{"key":"2025032809291913500_bib17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00262-019-02299-8","article-title":"The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma","volume":"68","author":"Agdashian","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025032809291913500_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","article-title":"Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma","volume":"26","author":"Fairfax","year":"2020","journal-title":"Nat Med"},{"key":"2025032809291913500_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med"},{"key":"2025032809291913500_bib20","doi-asserted-by":"crossref","first-page":"101435","DOI":"10.1016\/j.smim.2020.101435","article-title":"Memory CD8+ T cell responses to cancer","volume":"49","author":"Han","year":"2020","journal-title":"Semin Immunol"},{"key":"2025032809291913500_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3567","article-title":"Human memory T cells: generation, compartmentalization and homeostasis","volume":"14","author":"Farber","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2025032809291913500_bib22","doi-asserted-by":"crossref","first-page":"584423","DOI":"10.3389\/fimmu.2020.584423","article-title":"Tumor infiltrating effector memory antigen-specific CD8+ T cells predict response to immune checkpoint therapy","volume":"11","author":"Principe","year":"2020","journal-title":"Front Immunol"},{"key":"2025032809291913500_bib23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"2025032809291913500_bib24","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/1521-4141(200007)30:7<1823::AID-IMMU1823>3.0.CO;2-6","article-title":"Functionally distinct CD8+ memory T cell subsets in persistent EBV infection are differentiated by migratory receptor expression","volume":"30","author":"Tussey","year":"2000","journal-title":"Eur J Immunol"},{"key":"2025032809291913500_bib25","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy","volume":"111","author":"Hinrichs","year":"2008","journal-title":"Blood"},{"key":"2025032809291913500_bib26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00262-021-03087-z","article-title":"PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival","volume":"71","author":"N\u00fa\u00f1ez","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2025032809291913500_bib27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"2025032809291913500_bib28","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"2025032809291913500_bib29","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.26153","article-title":"Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma","volume":"57","author":"Mizukoshi","year":"2013","journal-title":"Hepatology"},{"key":"2025032809291913500_bib30","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"2025032809291913500_bib31","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1053\/jhep.2001.24026","article-title":"A molecular comparison of T lymphocyte populations infiltrating the liver and circulating in the blood of patients with chronic hepatitis B: evidence for antigen-driven selection of a public complementarity-determining region 3 (CDR3) motif","volume":"33","author":"Sing","year":"2001","journal-title":"Hepatology"},{"key":"2025032809291913500_bib32","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3390\/cancers15061808","article-title":"Adoptive cell therapy in hepatocellular carcinoma: a review of clinical trials","volume":"15","author":"Ozer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025032809291913500_bib33","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3389\/fimmu.2019.01336","article-title":"Clonality of CD4+ blood T cells predicts longer survival with CTLA4 or PD-1 checkpoint inhibition in advanced melanoma","volume":"10","author":"Arakawa","year":"2019","journal-title":"Front Immunol"},{"key":"2025032809291913500_bib34","doi-asserted-by":"crossref","first-page":"e20200921","DOI":"10.1084\/jem.20200921","article-title":"Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells","volume":"218","author":"Lucca","year":"2021","journal-title":"J Exp Med"},{"key":"2025032809291913500_bib35","doi-asserted-by":"crossref","first-page":"e004759","DOI":"10.1136\/jitc-2022-004759","article-title":"Single-cell analysis reveals clonally expanded tumor-associated CD57+ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade","volume":"10","author":"Fehlings","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025032809291913500_bib36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2025032809291913500_bib37","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-021-24343-x","article-title":"The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival","volume":"12","author":"Valpione","year":"2021","journal-title":"Nat Commun"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0228\/3481142\/crc-24-0228.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/8\/2163\/3485565\/crc-24-0228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/8\/2163\/3485565\/crc-24-0228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T14:05:51Z","timestamp":1743170751000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/8\/2163\/747032\/Yttrium-90-Induces-an-Effector-Memory-Response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0228","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.28684372","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780438.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780429.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780450.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780435.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780432.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780438","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780426","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28672570","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28672693","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28672564","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780426.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780450","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28672699","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780444","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780432","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780447","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780435","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780429","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28672696","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780441","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28672567","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28684369","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780447.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780444.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26780441.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28684375","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7408025.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7408025","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}